Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ischemic Heart Disease

  Free Subscription


Articles published in JAMA

Retrieve available abstracts of 91 articles:
HTML format
Text format



Single Articles


    December 2017
  1. GREENLAND P
    Cardiovascular Guideline Skepticism vs Lifestyle Realism?
    JAMA. 2017 Dec 14. pii: 2666625. doi: 10.1001/jama.2017.19675.
    PubMed     Text format    


    November 2017
  2. SLOMSKI A
    Evolocumab Reduces Cardiovascular Risk Regardless of Diabetes Status.
    JAMA. 2017;318:1968.
    PubMed     Text format    


  3. EMDIN CA, Khera AV, Kathiresan S
    Mendelian Randomization.
    JAMA. 2017;318:1925-1926.
    PubMed     Text format    


  4. IRONY TZ
    The "Utility" in Composite Outcome Measures: Measuring What Is Important to Patients.
    JAMA. 2017;318:1820-1821.
    PubMed     Text format    


  5. CHAPMAN AR, Lee KK, McAllister DA, Cullen L, et al
    Association of High-Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome.
    JAMA. 2017 Nov 11. doi: 10.1001/jama.2017.17488.
    PubMed     Text format     Abstract available


    October 2017
  6. ABBASI J
    Could a New Method to Detect Coronary Inflammation Prevent Heart Attacks?
    JAMA. 2017;318:1527-1528.
    PubMed     Text format    


    September 2017
  7. WADHERA RK, Bhatt DL
    Taking the "Public" Out of Public Reporting of Percutaneous Coronary Intervention.
    JAMA. 2017 Sep 28. doi: 10.1001/jama.2017.12087.
    PubMed     Text format    


  8. LICHTMAN JH, Jones MR, Leifheit EC, Sheffet AJ, et al
    Carotid Endarterectomy and Carotid Artery Stenting in the US Medicare Population, 1999-2014.
    JAMA. 2017;318:1035-1046.
    PubMed     Text format     Abstract available


  9. BARNARD ND, Willett WC, Ding EL
    The Misuse of Meta-analysis in Nutrition Research.
    JAMA. 2017 Sep 18. doi: 10.1001/jama.2017.12083.
    PubMed     Text format    


  10. DEVEREAUX PJ, Biccard BM, Chan MTV
    High-Sensitivity Troponin Levels, Ischemia, and Mortality-Reply.
    JAMA. 2017;318:865.
    PubMed     Text format    


  11. SMILOWITZ NR
    High-Sensitivity Troponin Levels, Ischemia, and Mortality.
    JAMA. 2017;318:864-865.
    PubMed     Text format    


    August 2017
  12. FERENCE BA, Kastelein JJP, Ginsberg HN, Chapman MJ, et al
    Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.
    JAMA. 2017 Aug 28. doi: 10.1001/jama.2017.11467.
    PubMed     Text format     Abstract available


  13. FELKER GM, Anstrom KJ, Adams KF, Ezekowitz JA, et al
    Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
    JAMA. 2017;318:713-720.
    PubMed     Text format     Abstract available


  14. CHOLLEY B, Caruba T, Grosjean S, Amour J, et al
    Effect of Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass: The LICORN Randomized Clinical Trial.
    JAMA. 2017;318:548-556.
    PubMed     Text format     Abstract available


  15. KRUMHOLZ HM
    Treatment of Cholesterol in 2017.
    JAMA. 2017;318:417-418.
    PubMed     Text format    


    July 2017
  16. LARSSON SC, Burgess S, Michaelsson K
    Association of Genetic Variants Related to Serum Calcium Levels With Coronary Artery Disease and Myocardial Infarction.
    JAMA. 2017;318:371-380.
    PubMed     Text format     Abstract available


  17. IOANNIDIS JPA
    Inconsistent Guideline Recommendations for Cardiovascular Prevention and the Debate About Zeroing in on and Zeroing LDL-C Levels With PCSK9 Inhibitors.
    JAMA. 2017 Jul 24. doi: 10.1001/jama.2017.6765.
    PubMed     Text format    


  18. DHARMARAJAN K, Wang Y, Lin Z, Normand ST, et al
    Association of Changing Hospital Readmission Rates With Mortality Rates After Hospital Discharge.
    JAMA. 2017;318:270-278.
    PubMed     Text format     Abstract available


  19. GROSSMAN DC, Bibbins-Domingo K, Curry SJ, Barry MJ, et al
    Behavioral Counseling to Promote a Healthful Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Cardiovascular Risk Factors: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2017;318:167-174.
    PubMed     Text format     Abstract available


  20. PATNODE CD, Evans CV, Senger CA, Redmond N, et al
    Behavioral Counseling to Promote a Healthful Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Known Cardiovascular Disease Risk Factors: Updated Evidence Report and Systematic Review for the US Preventive Services Tas
    JAMA. 2017;318:175-193.
    PubMed     Text format     Abstract available


  21. JIN J
    Counseling on Healthy Living to Prevent Cardiovascular Disease in Adults Without Risk Factors.
    JAMA. 2017;318:210.
    PubMed     Text format    


  22. YU J, Zhou Z, McEvoy RD, Anderson CS, et al
    Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea: A Systematic Review and Meta-analysis.
    JAMA. 2017;318:156-166.
    PubMed     Text format     Abstract available


  23. GOTTLIEB DJ
    Does Obstructive Sleep Apnea Treatment Reduce Cardiovascular Risk?: It Is Far Too Soon to Say.
    JAMA. 2017;318:128-130.
    PubMed     Text format    


  24. GREENLAND P, Fuster V
    Cardiovascular Risk Factor Control for All.
    JAMA. 2017;318:130-131.
    PubMed     Text format    


    June 2017
  25. BUDOFF MJ, Ellenberg SS, Snyder PJ
    Changes in Coronary Artery Plaque With Testosterone Therapy-Reply.
    JAMA. 2017;317:2451.
    PubMed     Text format    


  26. DHINDSA S, Wilson MF, Dandona P
    Changes in Coronary Artery Plaque With Testosterone Therapy.
    JAMA. 2017;317:2450.
    PubMed     Text format    


  27. NAVATHE AS, Song Z, Emanuel EJ
    The Next Generation of Episode-Based Payments.
    JAMA. 2017;317:2371-2372.
    PubMed     Text format    


  28. CHILDERS CP, Maggard-Gibbons M, Shekelle PG
    Antiplatelet Therapy in Patients With Coronary Stents Undergoing Elective Noncardiac Surgery: Continue, Stop, or Something in Between?
    JAMA. 2017 Jun 19. doi: 10.1001/jama.2017.7845.
    PubMed     Text format    


    May 2017
  29. SLOMSKI A
    Redefining Acute Coronary Syndrome Therapy.
    JAMA. 2017;317:2054.
    PubMed     Text format    


  30. ROTH GA, Dwyer-Lindgren L, Bertozzi-Villa A, Stubbs RW, et al
    Trends and Patterns of Geographic Variation in Cardiovascular Mortality Among US Counties, 1980-2014.
    JAMA. 2017;317:1976-1992.
    PubMed     Text format     Abstract available


  31. MENSAH GA, Goff DC, Gibbons GH
    Cardiovascular Mortality Differences-Place Matters.
    JAMA. 2017;317:1955-1957.
    PubMed     Text format    


    April 2017
  32. NICHOLLS SJ, Somaratne R, Nissen SE
    Evolocumab Added to Statins to Reduce Progression of Coronary Atherosclerosis-Reply.
    JAMA. 2017;317:1691.
    PubMed     Text format    


  33. ALKHALIL M, Choudhury RP
    Evolocumab Added to Statins to Reduce Progression of Coronary Atherosclerosis.
    JAMA. 2017;317:1690-1691.
    PubMed     Text format    


  34. MURRAY SW
    Evolocumab Added to Statins to Reduce Progression of Coronary Atherosclerosis.
    JAMA. 2017;317:1690.
    PubMed     Text format    


  35. DEVEREAUX PJ, Biccard BM, Sigamani A, Xavier D, et al
    Association of Postoperative High-Sensitivity Troponin Levels With Myocardial Injury and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery.
    JAMA. 2017;317:1642-1651.
    PubMed     Text format     Abstract available


  36. SCHWARTZ MLB, Williams MS, Murray MF
    Adding Protective Genetic Variants to Clinical Reporting of Genomic Screening Results: Restoring Balance.
    JAMA. 2017;317:1527-1528.
    PubMed     Text format    


    March 2017
  37. KHERA AV, Won HH, Peloso GM, O'Dushlaine C, et al
    Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease.
    JAMA. 2017;317:937-946.
    PubMed     Text format     Abstract available


    February 2017
  38. BUDOFF MJ, Ellenberg SS, Lewis CE, Mohler ER 3rd, et al
    Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone.
    JAMA. 2017;317:708-716.
    PubMed     Text format     Abstract available


  39. AGORITSAS T, Merglen A, Shah ND, O'Donnell M, et al
    Adjusted Analyses in Studies Addressing Therapy and Harm: Users' Guides to the Medical Literature.
    JAMA. 2017;317:748-759.
    PubMed     Text format     Abstract available


  40. BILECEN S, de Groot JA, Kalkman CJ, Spanjersberg AJ, et al
    Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High-Risk Cardiac Surgery: A Randomized Clinical Trial.
    JAMA. 2017;317:738-747.
    PubMed     Text format     Abstract available


  41. EMDIN CA, Khera AV, Natarajan P, Klarin D, et al
    Genetic Association of Waist-to-Hip Ratio With Cardiometabolic Traits, Type 2 Diabetes, and Coronary Heart Disease.
    JAMA. 2017;317:626-634.
    PubMed     Text format     Abstract available


    January 2017
  42. SILVERMAN MG, Im K, Sabatine MS
    Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk-Reply.
    JAMA. 2017;317:440.
    PubMed     Text format    


  43. ZAFAR K, Inayat M
    Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk.
    JAMA. 2017;317:439-440.
    PubMed     Text format    


  44. NAVARESE EP, Kolodziejczak M, De Servi S
    Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk.
    JAMA. 2017;317:439.
    PubMed     Text format    


  45. BRAGG F, Holmes MV, Iona A, Guo Y, et al
    Association Between Diabetes and Cause-Specific Mortality in Rural and Urban Areas of China.
    JAMA. 2017;317:280-289.
    PubMed     Text format     Abstract available


  46. GREENWOOD JP, Brown JM, Berry C
    Alternatives in the Evaluation of Suspected Coronary Heart Disease-Reply.
    JAMA. 2017;317:212-213.
    PubMed     Text format    


  47. SCHWITTER J
    Alternatives in the Evaluation of Suspected Coronary Heart Disease.
    JAMA. 2017;317:211-212.
    PubMed     Text format    


  48. BITTENCOURT MS, Fernandes JL
    Alternatives in the Evaluation of Suspected Coronary Heart Disease.
    JAMA. 2017;317:211.
    PubMed     Text format    


  49. FOROUZANFAR MH, Liu P, Roth GA, Ng M, et al
    Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015.
    JAMA. 2017;317:165-182.
    PubMed     Text format     Abstract available


    December 2016
  50. SLOMSKI A
    Celecoxib Similar to 2 NSAIDs for Cardiovascular Safety.
    JAMA. 2016;316:2589.
    PubMed     Text format    


  51. DESAI NR, Ross JS, Kwon JY, Herrin J, et al
    Association Between Hospital Penalty Status Under the Hospital Readmission Reduction Program and Readmission Rates for Target and Nontarget Conditions.
    JAMA. 2016;316:2647-2656.
    PubMed     Text format     Abstract available


  52. MORA S, Manson JE
    Shared Decision Making Regarding Aspirin in Primary Prevention of Cardiovascular Disease-Reply.
    JAMA. 2016;316:2276-2277.
    PubMed     Text format    


  53. STOVITZ SD, Satin DJ, Shrier I
    Shared Decision Making Regarding Aspirin in Primary Prevention of Cardiovascular Disease.
    JAMA. 2016;316:2276.
    PubMed     Text format    


    November 2016
  54. NICHOLLS SJ, Puri R, Anderson T, Ballantyne CM, et al
    Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
    JAMA. 2016 Nov 15. doi: 10.1001/jama.2016.16951.
    PubMed     Text format     Abstract available


  55. NAVAR AM, Peterson ED, Wojdyla D, Sanchez RJ, et al
    Temporal Changes in the Association Between Modifiable Risk Factors and Coronary Heart Disease Incidence.
    JAMA. 2016;316:2041-2043.
    PubMed     Text format    


  56. KAVOUSI M, Desai CS, Ayers C, Blumenthal RS, et al
    Prevalence and Prognostic Implications of Coronary Artery Calcification in Low-Risk Women: A Meta-analysis.
    JAMA. 2016 Nov 15. doi: 10.1001/jama.2016.17020.
    PubMed     Text format     Abstract available


  57. RODRIGUEZ F, Harrington RA
    Cholesterol, Cardiovascular Risk, Statins, PCSK9 Inhibitors, and the Future of LDL-C Lowering.
    JAMA. 2016;316:1967-1968.
    PubMed     Text format    


  58. BIBBINS-DOMINGO K, Grossman DC, Curry SJ, Davidson KW, et al
    Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2016;316:1997-2007.
    PubMed     Text format     Abstract available


  59. CHOU R, Dana T, Blazina I, Daeges M, et al
    Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2016;316:2008-2024.
    PubMed     Text format     Abstract available


  60. SONG Z, Blumenthal DM
    Expanding Payment Reform in Medicare: The Cardiology Episode-Based Payment Model.
    JAMA. 2016;316:1973-1974.
    PubMed     Text format    


  61. ABBASI J
    Do Apollo Astronaut Deaths Shine a Light on Deep Space Radiation and Cardiovascular Disease?
    JAMA. 2016 Nov 9. doi: 10.1001/jama.2016.12601.
    PubMed     Text format    


  62. LEGATO MJ, Johnson PA, Manson JE
    Consideration of Sex Differences in Medicine to Improve Health Care and Patient Outcomes.
    JAMA. 2016;316:1865-1866.
    PubMed     Text format    


    October 2016
  63. HAMPTON T
    Reservoir of Genetic Data Related to Cardiovascular Disease.
    JAMA. 2016;316:1349.
    PubMed     Text format    


  64. LOTTA LA, Sharp SJ, Burgess S, Perry JR, et al
    Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.
    JAMA. 2016;316:1383-1391.
    PubMed     Text format     Abstract available


    September 2016
  65. SILVERMAN MG, Ference BA, Im K, Wiviott SD, et al
    Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.
    JAMA. 2016;316:1289-97.
    PubMed     Text format     Abstract available


  66. MILLS K, He J
    Sodium Excretion, Cardiovascular Disease, and Chronic Kidney Disease.
    JAMA. 2016;316:1112-3.
    PubMed     Text format    


  67. ALMIRALL J
    Sodium Excretion, Cardiovascular Disease, and Chronic Kidney Disease.
    JAMA. 2016;316:1112.
    PubMed     Text format    


  68. HURSITOGLU M
    Sodium Excretion, Cardiovascular Disease, and Chronic Kidney Disease.
    JAMA. 2016;316:1112.
    PubMed     Text format    


  69. HEMKENS LG, Ewald H, Briel M
    Colchicine and Prevention of Cardiovascular Events.
    JAMA. 2016;316:1106-7.
    PubMed     Text format     Abstract available


    August 2016
  70. HALL M, Dondo TB, Yan AT, Goodman SG, et al
    Association of Clinical Factors and Therapeutic Strategies With Improvements in Survival Following Non-ST-Elevation Myocardial Infarction, 2003-2013.
    JAMA. 2016 Aug 30. doi: 10.1001/jama.2016.10766.
    PubMed     Text format     Abstract available


  71. BOHULA EA, Antman EM
    Management of Non-ST-Elevation Myocardial Infarction: The Bright Gleam of Progress, But Much Work Remains.
    JAMA. 2016 Aug 30. doi: 10.1001/jama.2016.11940.
    PubMed     Text format    


  72. GREENWOOD JP, Ripley DP, Berry C, McCann GP, et al
    Effect of Care Guided by Cardiovascular Magnetic Resonance, Myocardial Perfusion Scintigraphy, or NICE Guidelines on Subsequent Unnecessary Angiography Rates: The CE-MARC 2 Randomized Clinical Trial.
    JAMA. 2016 Aug 29. doi: 10.1001/jama.2016.12680.
    PubMed     Text format     Abstract available


  73. KAZI DS, Moran AE, Coxson PG, Penko J, et al
    Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    JAMA. 2016;316:743-53.
    PubMed     Text format     Abstract available


  74. LIVINGSTON EH
    JAMA PATIENT PAGE. Screening for Lipid Disorders in Children and Adolescents.
    JAMA. 2016;316:678.
    PubMed     Text format    


  75. LOZANO P, Henrikson NB, Dunn J, Morrison CC, et al
    Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2016;316:645-55.
    PubMed     Text format     Abstract available


  76. LOZANO P, Henrikson NB, Morrison CC, Dunn J, et al
    Lipid Screening in Childhood and Adolescence for Detection of Multifactorial Dyslipidemia: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2016;316:634-44.
    PubMed     Text format     Abstract available


    July 2016
  77. NUTI SV, Qin L, Krumholz HM
    Outcome After Admission at Veterans Affairs vs Non-Veterans Affairs Hospitals--Reply.
    JAMA. 2016;316:346.
    PubMed     Text format    


  78. RADOMSKI TR, Fine MJ, Gellad WF
    Outcome After Admission at Veterans Affairs vs Non-Veterans Affairs Hospitals.
    JAMA. 2016;316:345-6.
    PubMed     Text format    


    June 2016
  79. CHOBANIAN AV
    SPRINT Results in Older Patients: How Low to Go?
    JAMA. 2016;315:2669-70.
    PubMed     Text format    


  80. GANZ P, Heidecker B, Hveem K, Jonasson C, et al
    Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease.
    JAMA. 2016;315:2532-41.
    PubMed     Text format     Abstract available


  81. SABATINE MS
    Using Aptamer-Based Technology to Probe the Plasma Proteome for Cardiovascular Disease Prediction.
    JAMA. 2016;315:2525-6.
    PubMed     Text format    


  82. MORA S, Ames JM, Manson JE
    Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease: Shared Decision Making in Clinical Practice.
    JAMA. 2016 Jun 20. doi: 10.1001/jama.2016.8362.
    PubMed     Text format    


  83. HONG SJ, Kim BK, Hong MK
    Ultrasound vs Angiography for Drug-Eluting Stent Implantation--Reply.
    JAMA. 2016;315:2469-70.
    PubMed     Text format    


  84. STEINVIL A, Waksman R, Garcia-Garcia HM
    Ultrasound vs Angiography for Drug-Eluting Stent Implantation.
    JAMA. 2016;315:2469.
    PubMed     Text format    


  85. TUNCEZ A, Altunkeser BB
    Ultrasound vs Angiography for Drug-Eluting Stent Implantation.
    JAMA. 2016;315:2468-9.
    PubMed     Text format    


  86. HOFFER EK
    Ultrasound vs Angiography for Drug-Eluting Stent Implantation.
    JAMA. 2016;315:2468.
    PubMed     Text format    


  87. MANSON JE, Shufelt CL, Robins JM
    The Potential for Postrandomization Confounding in Randomized Clinical Trials.
    JAMA. 2016;315:2273-4.
    PubMed     Text format    


    May 2016
  88. MILLS KT, Chen J, Yang W, Appel LJ, et al
    Sodium Excretion and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease.
    JAMA. 2016;315:2200-10.
    PubMed     Text format     Abstract available


  89. POWE NR, Bibbins-Domingo K
    Dietary Salt, Kidney Disease, and Cardiovascular Health.
    JAMA. 2016;315:2173-4.
    PubMed     Text format    


  90. WILLIAMSON JD, Supiano MA, Applegate WB, Berlowitz DR, et al
    Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged >/=75 Years: A Randomized Clinical Trial.
    JAMA. 2016 May 19. doi: 10.1001/jama.2016.7050.
    PubMed     Text format     Abstract available


    April 2016
  91. PENCINA MJ, Peterson ED
    Moving From Clinical Trials to Precision Medicine: The Role for Predictive Modeling.
    JAMA. 2016;315:1713-4.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Ischemic Heart Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: